A5225

A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis

Sponsor: US National Institute of Allergy and Infectious Diseases (NIAID)

Protocol Summary: A5225 was a phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an induction-consolidation strategy of high-dose fluconazole alone for the treatment of cryptococcal meningitis (CM) in HIV-infected participants.

Years: 2010 – present

Investigator: James Hakim, MBChB, FRCP

Location: Parirenyatwa CRS

ACTG

Completed Study

Publication:

Comments are closed.

Website by Canton Becker